論文

査読有り 国際誌
2018年2月13日

Effective impairment of myeloma cells and their progenitors by hyperthermia.

Oncotarget
  • Hirokazu Miki
  • Shingen Nakamura
  • Asuka Oda
  • Hirofumi Tenshin
  • Jumpei Teramachi
  • Masahiro Hiasa
  • Ariunzaya Bat-Erdene
  • Yusaku Maeda
  • Masahiro Oura
  • Mamiko Takahashi
  • Masami Iwasa
  • Takeshi Harada
  • Shiro Fujii
  • Kiyoe Kurahashi
  • Sumiko Yoshida
  • Kumiko Kagawa
  • Itsuro Endo
  • Kenichi Aihara
  • Mariko Ikuo
  • Kohji Itoh
  • Koichiro Hayashi
  • Michihiro Nakamura
  • Masahiro Abe
  • 全て表示

9
12
開始ページ
10307
終了ページ
10316
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18632/oncotarget.23121

Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance. We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death. The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated "side population" fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by in vitro colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs.

リンク情報
DOI
https://doi.org/10.18632/oncotarget.23121
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29535808
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828190
ID情報
  • DOI : 10.18632/oncotarget.23121
  • ISSN : 1949-2553
  • PubMed ID : 29535808
  • PubMed Central 記事ID : PMC5828190

エクスポート
BibTeX RIS